Stryker Corporation $SYK Holdings Lifted by Cerity Partners LLC

Cerity Partners LLC increased its holdings in Stryker Corporation (NYSE:SYK) by 1.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 317,999 shares of the medical technology company’s stock after acquiring an additional 3,419 shares during the period. Cerity Partners LLC owned about 0.08% of Stryker worth $117,554,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Brighton Jones LLC lifted its position in shares of Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares in the last quarter. State of Wyoming acquired a new position in Stryker in the 1st quarter valued at approximately $62,000. Kestra Investment Management LLC lifted its position in Stryker by 199.1% in the 1st quarter. Kestra Investment Management LLC now owns 329 shares of the medical technology company’s stock worth $122,000 after buying an additional 219 shares in the last quarter. Signature Estate & Investment Advisors LLC boosted its stake in shares of Stryker by 4.1% during the 1st quarter. Signature Estate & Investment Advisors LLC now owns 1,538 shares of the medical technology company’s stock valued at $572,000 after buying an additional 61 shares during the period. Finally, Meiji Yasuda Asset Management Co Ltd. grew its holdings in shares of Stryker by 6.9% during the 1st quarter. Meiji Yasuda Asset Management Co Ltd. now owns 7,670 shares of the medical technology company’s stock valued at $2,855,000 after acquiring an additional 498 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. The trade was a 9.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO William E. Berry, Jr. sold 1,953 shares of the firm’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the sale, the chief accounting officer directly owned 2,833 shares in the company, valued at approximately $1,035,433.17. This represents a 40.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 522,118 shares of company stock worth $185,381,932 in the last quarter. 5.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

SYK has been the subject of several recent research reports. Barclays increased their price objective on Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Raymond James Financial upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target for the company in a report on Tuesday. Redburn Partners set a $420.00 price target on Stryker in a research note on Thursday, September 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $448.00 price objective on shares of Stryker in a research report on Friday, November 14th. Finally, UBS Group set a $408.00 target price on shares of Stryker in a research report on Monday, October 13th. Fourteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $430.40.

Stryker Stock Up 5.1%

Shares of SYK stock opened at $366.46 on Wednesday. The stock’s 50 day simple moving average is $359.75 and its 200 day simple moving average is $375.35. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.13 and a current ratio of 1.85. The company has a market capitalization of $140.14 billion, a price-to-earnings ratio of 48.16, a PEG ratio of 2.23 and a beta of 0.89.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Friday, October 31st. The medical technology company reported $3.19 EPS for the quarter, beating the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The company had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter last year, the company posted $2.87 earnings per share. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. As a group, research analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Wednesday, December 31st will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Wednesday, December 31st. This is a boost from Stryker’s previous quarterly dividend of $0.84. Stryker’s dividend payout ratio (DPR) is 46.25%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.